Extended Data Fig. 1: Individual tumor growth curves for the experiments presented in main Fig. 3.
From: Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
a, Individual tumor growth curves for MC38 tumor-bearing mice (n = 6) treated intraperitoneally with the indicated VHHs at 5 mg/kg on day 1 post-tumor injection, followed by three times a week for 3 weeks as indicated by the arrows. b, Individual tumor growth curves for B16-F10 tumor-bearing mice (n = 6) treated intraperitoneally with the indicated VHHs at 5 mg/kg on day 1 post-tumor injection, followed by three times a week for 3 weeks as indicated by the arrows. The mice were vaccinated with GM-CSF–secreting B16 cells (GVAX) on day 0. c, Individual tumor growth curves for MC38 tumor-bearing mice (n = 6) treated intravenously with the indicated VHHs at 5 mg/kg or antibody at 12.5 mg/kg on day 7, 10, and 13 post-tumor injection as indicated by the arrows. d, Tumor growth (left) and survival curves (middle) for MC38 tumor-bearing mice (Data represent mean ± SD, n = 6) treated intravenously with the anti-CTLA-4 VHH (H11)-VHHkappa conjugate at 5 mg/kg and 2.5 mg/kg on day 7, 10, and 13 post-tumor injection as indicated by the arrows. † Mouse was sacrificed due to severe ulceration of its tumor. This is part of the study presented in Fig. 3f. Right: Individual tumor growth curves for mice treated with 2.5 mg/kg of the H11-VHHkappa conjugate. (Two-way ANOVA with Bonferroni’s correction for multiple comparisons was used to analyze the tumor growth curves. The two-sided Log-rank (Mantel-Cox) test was applied to analyze the survival curves.).
